Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation

Gao, Lulu; Ma, Jia-Min; Fan, Yanna; Zhang, Yannan; Ge, Rui; Tao, Xiujuan; Zhang, Mengwei; Gao, Qing‐Han; Yang, Jianjun

doi:10.1016/j.ijbiomac.2021.05.066

Cited by 86 publications

(45 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LBP has been reported to modulate immune function and to be effective in anti-inflammation ( Jin et al., 2013 ; Zhao et al., 2014 ). It has also been reported to interact with the gut microbiome ( Cui et al., 2020 ; Zhu et al., 2020 ; Gao et al., 2021 ). Further separation and purification of natural food supplements and search for active ingredients are needed.…”

Section: Introductionmentioning

confidence: 99%

Lycium barbarum Glycopeptide prevents the development and progression of acute colitis by regulating the composition and diversity of the gut microbiota in mice

Huang

Zheng

Yang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

In most cases, recurrent chronic colitis is caused by the recurrence of acute colitis after incomplete recovery and re-exposure to irritating factors, and the gut microbiome, which is the largest micro-ecosystem in the human body, plays a crucial role in the development of colitis. Plant polysaccharides have always been reported to have the ability for anti-inflammation, and they are closely related to the gut microbiome. Lycium barbarum Glycopeptide (LbGP), the most potent component obtained by further isolation and purification from Lycium barbarum fruit, has been shown to inhibit inflammation in animal models. However, its therapeutic efficacy in colitis and its mechanism in gut microbiota regulation have not been fully studied. In our study, the dextran sulfate sodium (DSS)-induced mouse model was used to dynamically evaluate the effect of LbGP in the treatment of acute colitis and the mechanism from the perspective of the gut microbiome through the 16S rDNA sequence. The results showed that LbGP treatment significantly alleviated acute colitis and improved the gut microbiome compared with that in the model group. Harmful bacteria, such as Lachnoclostridium spp. and Parabacteroides_distasonis, were inhibited and probiotics, such as Bacteroides_acidifaciens, Lactobacillus spp., Turicibacter spp., and Alistipes spp., were increased by LbGP treatment. Further, a Random Forest analysis with 10-fold cross-validation identified a family named Muribaculaceae representing colitis development and recovery upon LbGP treatment. In conclusion, our study demonstrated the capability of LbGP to prevent the development of acute colitis by regulating the composition and diversity of the gut microbiota and highlighted the dynamic process of gut microbiota with the colitis progression. Further, it provides evidence to develop LbGP as a functional food supplement and future drug acting on intestinal disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Lycium barbarum Glycopeptide prevents the development and progression of acute colitis by regulating the composition and diversity of the gut microbiota in mice

Huang

Zheng

Yang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Lycium barbarum polysaccharides (LBP), which are composed of a fibrous-like proteoglycan, are the main bioactive components of the traditional medicinal herb, Lycium barbarum L . (Chinese wolfberry), and have a variety of pharmacological functions, including immunomodulatory and antioxidant activities ( Liu et al, 2017 ; Gao et al, 2021 ). In a rat model of NASH, administration of LBP for the treatment of steatosis exhibited therapeutic efficiency, reducing hepatic fibrosis and inflammation ( Jia et al, 2016 ).…”

Section: Pharmacological Agents Associated With Nlrp3 Inflammasome Su...mentioning

confidence: 99%

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver diseases worldwide and can develop into various conditions, ranging from simple steatosis, through non-alcoholic steatohepatitis (NASH), to fibrosis, and eventually cirrhosis and hepatocellular carcinoma. Nevertheless, there is no effective treatment for NAFLD due to the complicated etiology. Recently, activation of the NLPR3 inflammasome has been demonstrated to be a contributing factor in the development of NAFLD, particularly as a modulator of progression from initial hepatic steatosis to NASH. NLRP3 inflammasome, as a caspase-1 activation platform, is critical for processing key pro-inflammatory cytokines and pyroptosis. Various stimuli involved in NAFLD can activate the NLRP3 inflammasome, depending on the diverse cellular stresses that they cause. NLRP3 inflammasome-related inhibitors and agents for NAFLD treatment have been tested and demonstrated positive effects in experimental models. Meanwhile, some drugs have been applied in clinical studies, supporting this therapeutic approach. In this review, we discuss the activation, biological functions, and treatment targeting the NLRP3 inflammasome in the context of NAFLD progression. Specifically, we focus on the different types of therapeutic agents that can inhibit the NLRP3 inflammasome and summarize their pharmacological effectiveness for NAFLD treatment.

show abstract

“…However, the intestinal permeability measured by D-mannitol recovery was not affected by the oligosaccharide intake [ 128 ]. Gao et al [ 129 ] evaluated the effect of Lycium barbarum polysaccharides (LBPs), alone or together with aerobic exercise, on the intestinal microbiota, gut barrier function and hepatic inflammation in rats with nonalcoholic fatty liver disease (NAFLD). Intake of LBP in a dose of 50 mg/kg for eight weeks together or without aerobic activity upregulated the expression of ZO-1 and occludin in the colon.…”

Section: Prebioticsmentioning

confidence: 99%

Overview of the Importance of Biotics in Gut Barrier Integrity

Kocot

Jarocka-Cyrta

Drabińska

2022

IJMS

View full text Add to dashboard Cite

Increased gut permeability is suggested to be involved in the pathogenesis of a growing number of disorders. The altered intestinal barrier and the subsequent translocation of bacteria or bacterial products into the internal milieu of the human body induce the inflammatory state. Gut microbiota maintains intestinal epithelium integrity. Since dysbiosis contributes to increased gut permeability, the interventions that change the gut microbiota and correct dysbiosis are suggested to also restore intestinal barrier function. In this review, the current knowledge on the role of biotics (probiotics, prebiotics, synbiotics and postbiotics) in maintaining the intestinal barrier function is summarized. The potential outcome of the results from in vitro and animal studies is presented, and the need for further well-designed randomized clinical trials is highlighted. Moreover, we indicate the need to understand the mechanisms by which biotics regulate the function of the intestinal barrier. This review is concluded with the future direction and requirement of studies involving biotics and gut barrier.

show abstract

Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation

Cited by 86 publications

References 56 publications

Lycium barbarum Glycopeptide prevents the development and progression of acute colitis by regulating the composition and diversity of the gut microbiota in mice

Lycium barbarum Glycopeptide prevents the development and progression of acute colitis by regulating the composition and diversity of the gut microbiota in mice

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Overview of the Importance of Biotics in Gut Barrier Integrity

Contact Info

Product

Resources

About